コンテンツへスキップ
Merck

主要文書

すべての文書を表示

HSTCMAG28SPMX13

MILLIPLEX®ヒト高感度T細胞パネルプレミックス13プレックス - 免疫学マルチプレックスアッセイ

Premixed 96-well Human High Sensitivity T Cell 13-Plex Panel

別名:

Human high-sensitivity cytokine multiplex kit, Luminex® human high-sensitivity cytokine immunoassay, Millipore human high-sensitivity cytokine panel

ログインで組織・契約価格をご覧ください。

サイズを選択してください

表示を変更する

この商品について

UNSPSC Code:
12161503
NACRES:
NA.47
eCl@ss:
32161000
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします

製品名

MILLIPLEX®ヒト高感度T細胞パネルプレミックス13プレックス - 免疫学マルチプレックスアッセイ,

Quality Level

200

description

Premixed 96-well Human High Sensitivity T Cell 13-Plex Panel

species reactivity

human

packaging

pkg of 1 ea

manufacturer/tradename

Milliplex®

technique(s)

multiplexing: suitable

input

plasma
cell culture supernatant(s)
serum

assay range

accuracy: 98-107%, sensitivity: 0.11-8.17 pg/mL
(Overnight Incubation minDC), standard curve range: 0.18-750 pg/mL
(IL-6), standard curve range: 0.24-1,000 pg/mL
(IL-13), standard curve range: 0.31-1,250 pg/mL
(IL-8), standard curve range: 0.37-1,500 pg/mL
(IL-7), standard curve range: 0.45-1,750 pg/mL
(TNFα), standard curve range: 0.49-2,000 pg/mL
(IL-1β), standard curve range: 0.49-2,000 pg/mL
(IL-12 (p70)), standard curve range: 0.49-2,000 pg/mL
(IL-2), standard curve range: 0.49-2,000 pg/mL
(IL-5), standard curve range: 0.61-2,500 pg/mL
(IFNγ), standard curve range: 1.22-5,000 pg/mL
(GM-CSF), standard curve range: 1.46-6,000 pg/mL
(IL-10), standard curve range: 1.83-7,500 pg/mL
(IL-4), inter-assay cv: <15%
intra-assay cv: <10%

detection method

fluorometric (Luminex® xMAP® technology)

shipped in

wet ice

storage temp.

2-8°C

General description

Cytokines are immunomodulatory polypeptides that play key roles in both adaptive and innate immune responses. One of the regulatory mechanisms of the immune system, cytokines act at the recognition, activation, or effector phases of an immune response, modulating the development and functional activities of the subtypes of T cells, B cells and myeloid cells. Consequently, research involving cytokines plays a significant role in achieving a deeper understanding of the immune system and its multi-faceted response to most antigens, especially those responses that make up the inflammatory process. Low levels of inflammation are involved in many sub-clinical disease states, such as autoimmune disease, cardiovascular disease, diabetes, neurological disorders, and cancer. Measuring picogram levels of cytokines, therefore, is critical for understanding the pathogenesis of these diseases.

Application

MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze 13 analytes in human serum, plasma, and cell culture supernatants.

Analytes included: GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, TNF-α

Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

Features and Benefits

  • Time-Saving: Reduces assay time and labor compared to running multiple ELISAs.
  • Efficient Sample Use: Conserves valuable sample volume by measuring multiple analytes in one well.
  • Premixed Magnetic Beads: Ready-to-use, pre-plexed beads for 13 analytes, reducing hands-on time and eliminating manual bead mixing errors.
  • Verified Specificity: No detectable cross-reactivity among analytes with accuracy ranges from 98% to 107%.

Legal Information

Luminex is a registered trademark of Luminex Corporation
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

For research use only. Not for use in diagnostic procedures.

Label License/Sticker for Assay Product:

By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

Still not finding the right product?

Explore all of our products under MILLIPLEX®ヒト高感度T細胞パネルプレミックス13プレックス - 免疫学マルチプレックスアッセイ

signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

保管分類

10 - Combustible liquids

wgk

WGK 3

適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

キットコンポーネントの情報を参照してください

pdsc

キットコンポーネントの情報を参照してください

prtr

キットコンポーネントの情報を参照してください

fsl

キットコンポーネントの情報を参照してください

ishl_indicated

キットコンポーネントの情報を参照してください

ishl_notified

キットコンポーネントの情報を参照してください

cart

キットコンポーネントの情報を参照してください

jan

試験成績書（COA）

製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Pavlos Msaouel et al.
Oncotarget, 8(26), 42149-42158 (2017-02-09)
No biomarkers are available to predict relative clinical benefit from targeted therapies in patients with non-clear cell renal cell carcinoma (nccRCC). To identify candidate predictive markers, we investigated a set of cytokines and angiogenic factors (CAFs) in previously untreated patients
Tatum Sevenoaks et al.
Brain, behavior, and immunity, 91, 65-73 (2020-08-30)
HIV-exposed uninfected (HEU) children may have altered immune regulation and poorer neurodevelopment outcomes compared to their HIV-unexposed (HU) counterparts. However, studies investigating the association of maternal and infant inflammation with neurodevelopment in HEU children are limited and longitudinal data are
Emily Han-Chung Hsiue et al.
Science (New York, N.Y.), 371(6533) (2021-03-03)
TP53 (tumor protein p53) is the most commonly mutated cancer driver gene, but drugs that target mutant tumor suppressor genes, such as TP53, are not yet available. Here, we describe the identification of an antibody highly specific to the most
関連する文献をすべて表示

グローバルトレードアイテム番号

カタログ番号GTIN
HSTCMAG28SPMX1304055977289107